BRAF and neoplasm: As shown in Figures 7E and S8, both tumor growth and tumor weight were significantly reduced in mice receiving BRAFi/AKTi combination compared to the monotherapies (Figures 7E and S8), confirming that AKT signaling pathway plays a role in the in vivo responses of BRAF-mutant tumors to PLX4032.